|Bid||7.14 x 800|
|Ask||7.12 x 1800|
|Day's Range||6.76 - 7.22|
|52 Week Range||2.37 - 9.93|
|Beta (3Y Monthly)||2.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, will be presenting at the Dawson James Securities Small Cap Growth Conference on Tuesday, October 29th at 10:55 a.m. ET. To access the live webcast and subsequent archived recordings for the presentation, please visit the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/. Dawson James Securities, Inc., a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL.
CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. We at CEL-SCI have been believers in the value of immunotherapy for treating cancer for decades before others recognized it’s potential. Now cancer immunotherapy has gone from “cannot work” to “this is the future”.
CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The IDMC meets periodically to review the safety and efficacy of the ongoing Phase 3 study.
CEL-SCI Corporation (NYSE American: CVM) is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 10:40 a.m. PT. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation. Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.
CEL-SCI Corporation today reported financial results for the quarter ended March 31, 2019. The Company also reported key clinical and corporate developments achieved during the quarter.
This new LEAPS conjugate appears to act on T cell pathways by a new mechanism that is different from the pathways used by the CEL-4000 vaccine. CEL-SCI Corporation (NYSE American: CVM) announced today that Daniel Zimmerman, Ph.D., its Senior Vice President of Research, Cellular Immunology, presented new LEAPS data at the American Association of Immunologists 103th Annual Meeting (Immunology 2019) in San Diego, California on Saturday, May 11, 2019.
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the ThinkEquity Conference in New York, NY on Thursday, May 2, 2019 at 1:00 p.m. A live audio webcast of the presentation and replay will be available on CEL-SCI's website at https://cel-sci.com/new-investor-information/. CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival.
NEW YORK, March 26, 2019 -- Levi & Korsinsky announces it has commenced an investigation of CEL-SCI Corporation (NYSEAMERICAN: CVM) concerning possible breaches of.
CEL-SCI Corporation (NYSE American: CVM) today announced it has been selected by the U.S. National Institutes of Health (NIH) for sponsorship to exhibit and showcase its presentation for its LEAPS technology at the BIO International Convention, to be held June 3-6, 2019 in Philadelphia. LEAPS, which is currently being developed as a therapeutic vaccine for rheumatoid arthritis under a $1.5 million SBIR/STTR grant from the NIH, will be featured at the convention’s Innovation Zone, a turn-key exhibit space dedicated to showcasing select NIH SBIR/STTR awardees.
CEL-SCI Corporation (NYSE American:CVM) today announced the Journal of Clinical & Cellular Immunology has published an article titled, “Why Don’t We Have a Vaccine Against Autoimmune Diseases?” co-written by Dr. Ken Rosenthal of Roseman University College of Medicine, and CEL-SCI’s Roy Carambula, Research Associate and Daniel Zimmerman Ph.D., Senior Vice President of Cellular Immunology.
CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at 2:00 p.m. A live audio webcast of the presentation and replay will be available on CEL-SCI's website at https://cel-sci.com/new-investor-information/. Now in its 21st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
CEL-SCI Corporation (NYSE American: CVM) today announced the U.S. Patent and Trademark Office has issued two new U.S. patents for the Company’s LEAPS platform technology. CEL-SCI’s LEAPS inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.
CEL-SCI Corporation (NYSE American: CVM) today announced that it has received notification from the staff of the NYSE American, its current listing exchange, that the Company is now considered in full compliance with the continued listing requirements. The Company previously received notice on July 12, 2018, indicating that the Company was not in compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the listing requirements of the Exchange since it reported a stockholders’ equity deficit as of March 31, 2018 and had net losses in its 5 most recent fiscal years ended September 30, 2017.
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.